Aptevo Therapeutics (APVO) EBIAT (2016 - 2025)
Aptevo Therapeutics (APVO) has disclosed EBIAT for 11 consecutive years, with -$5.8 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 8.02% to -$5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$26.0 million through Dec 2025, down 7.61% year-over-year, with the annual reading at -$26.0 million for FY2025, 7.61% down from the prior year.
- EBIAT hit -$5.8 million in Q4 2025 for Aptevo Therapeutics, up from -$7.5 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $28.0 million in Q2 2022 to a low of -$7.9 million in Q2 2023.
- Historically, EBIAT has averaged -$4.5 million across 5 years, with a median of -$6.4 million in 2023.
- Biggest five-year swings in EBIAT: crashed 350.47% in 2021 and later soared 453.13% in 2022.
- Year by year, EBIAT stood at -$7.2 million in 2021, then grew by 28.52% to -$5.2 million in 2022, then decreased by 14.33% to -$5.9 million in 2023, then dropped by 6.93% to -$6.3 million in 2024, then increased by 8.02% to -$5.8 million in 2025.
- Business Quant data shows EBIAT for APVO at -$5.8 million in Q4 2025, -$7.5 million in Q3 2025, and -$6.2 million in Q2 2025.